The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
News|Articles|February 13, 2019
Ultomiris for Paroxysmal Nocturnal Hemoglobinuria
Author(s)Drew Boxler
Advertisement
ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)
Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria
Dosage: intravenous infusion only
- 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance
- 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance
- 100kg ≤ X – 3,000mg leading, 3,600 maintenance
Contraindications: patients with unresolved Neisseria Meningitidis infection.
Advertisement
Related to this article
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
3
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
4
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
5